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Impact and novelty:  There remains an unmet clinical need for therapeutic targets and 
diagnostic biomarkers in cancer cachexia.  The current study is the largest investigation 
to date to systematically analyse potential skeletal muscle biomarkers of cancer 
cachexia related to weight-loss and survival in humans.  Akt protein 
levels/phosphorylation status and GABARAPL1 expression are identified as novel 
biomarkers relating to cancer/early cachexia, β-dystroglycan as a biomarker of weight-
loss and myosin heavy-chain and dystrophin as biomarkers associated with survival. 
 
Abstract 
In order to grow the potential therapeutic armamentarium in the cachexia domain of 
supportive oncology there is a pressing need to develop suitable biomarkers and 
potential drug targets. This pilot study evaluated several potential candidate biomarkers 
in skeletal muscle biopsies from a cohort of upper gastrointestinal cancer (UGIC) 
patients.  107 patients (15 weight-stable healthy controls (HC), 92 UGIC patients) were 
recruited.  Mean (SD) weight-loss of UGIC patients was 8.1 (9.3)%. Cachexia was 
defined as weight-loss ≥5%. Rectus abdominis muscle was obtained at surgery and 
analysed by Western blotting or qRT-PCR for Akt/phosphorylated-Akt (n=52), 
FOXO1/3a, MAFBx, MuRF1, BNIP3, GABARAPL1 (n=59), myosin heavy-chain 
(MyHC, n=54), dystrophin (n=39), β-dystroglycan and β-sarcoglycan (n=52). Patients 
were followed up for an average of 1255 days (range 581-1955 days) or until death.  
Cancer patients compared with HC, had reduced total Akt protein (p=0.001), increased 
ratio of phosphorylated to total Akt (p=0.002) and increased expression of 
GABARAPL1 (p=0.024). β-dystroglycan levels were higher in cachectic compared with 
non-cachectic cancer patients (p=0.007). Survival was shortened in patients with low 
MyHC levels or low dystrophin levels (p=0.023 and p=0.008 respectively).  The present 
study has identified intramuscular protein level of β-dystroglycan as a potential 
biomarker of cancer cachexia.  Changes in the structural elements of muscle (MyHC or 
dystrophin) appear to be survival biomarkers.   
Introduction 
Cancer cachexia represents an important, yet often under-appreciated cause of patient 
morbidity and mortality.  It is “a multifactorial syndrome defined by an ongoing loss of 
skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by 
conventional nutritional support and leads to progressive functional impairment” (1).  
Cachexia is due to a combination of reduced food intake and metabolic change.  The 
prevalence of cachexia varies with tumour type and stage and may also vary with the 
genotype of the host (2).  Affected individuals face increased risks of treatment failure 
(be it chemotherapy, radiotherapy or surgery), increased risks of treatment side-effects 
and an increased mortality rate (1;3).   
 
Cachexia in its advanced phase (where patients may have lost 20-30% of their body 
weight) is easily identified, but by this stage, it is often impossible to undertake any 
realistic form of multimodal rehabilitation.  Thus, it might be useful to identify patients 
who are at risk or in the early phase of cancer cachexia so that targeted intervention can 
be instituted.  An early intervention approach has been hampered by a limited 
understanding of the molecular pathways implicated in human cancer cachexia along 
with a lack of validated biomarkers.  For example, although elevated serum C-reactive 
protein (CRP) is a robust indicator of systemic inflammation and has been linked to 
both cancer-associated hypermetabolism, reduced food intake and shortened survival (4), 
in a multivariate model of weight-loss in upper gastrointestinal patients, the estimate of 
size of effect on degree of weight-loss for CRP was only 34% (5).  Loss of skeletal 
muscle has been identified as the central characteristic of cancer cachexia (1).  We 
hypothesised that either alteration in pathways of muscle atrophy or in the components 
of muscle itself might provide more robust biomarkers.   
 
Muscle wasting occurs as a result of an imbalance between protein synthesis and 
degradation.   Evidence from animal models of muscle atrophy suggests that the 
catabolic ubiquitin proteasome pathway (UPP) and autophagy pathway are of key 
importance (6-10). Despite this knowledge, there remains limited data relating to human 
cancer cachexia.  A few studies have identified potential biomarkers of cachexia in 
various tissue compartments using different methodological approaches (2;11-14).  As a 
useful addition to this emerging body of work, we sought to identify potential clinically 
relevant cachectic biomarkers in skeletal muscle biopsies from upper gastrointestinal 
cancer (UGIC) patients in relation to weight-loss and post-operative survival.  
Candidate markers were selected according to previous literature and included Akt and 
phosphorylated Akt (pAkt), FOXO transcription factors, ubiquitin E3 ligases (control of 
muscle anabolism/catabolism) (6-8;15;16), BNIP3 and GABARAPL1 (as markers of 
autophagy) (6;9;17;18), myosin heavy-chain (MyHC), dystrophin, β-dystroglycan and 
β-sarcoglycan (as markers of structural alteration in muscle) (7;10;19;20). 
 
Materials and Methods 
Subjects 
92 consecutive UGIC patients (with a diagnosis of oesophago-gastric (n=56), small 
bowel (n=2), pancreatic (n=33) or common bile duct (n=1) malignancy) undergoing 
potentially curative surgery were recruited.  16 patients had stage IV disease, 38 patients 
had stage III, 23 patients had stage II and 15 patients had stage I disease.  Patients (n=27) 
who had completed a course of neoadjuvant chemotherapy had not received 
chemotherapy in the four weeks prior to surgery/biopsy. No subjects were knowingly 
taking anabolic/catabolic agents, had uncontrolled diabetes or thyroid disorders. The 
weight-stable healthy controls (HC) comprised 15 subjects undergoing abdominal 
surgery for non-malignant, non-inflammatory conditions. Written informed consent was 
obtained from all subjects and ethical approval received from Lothian Research Ethics 
Committee (UK). UGIC patients were followed up for an average of 1255 days (range 
581-1955 days) post-operatively or until death. 
 
Anthropometry, weight-loss and performance status 
Body weight was measured in light clothing using a beam scale (Seca, UK).  Height 
was measured using a standard wall-mounted measure.  The patients’ clinical details 
were recorded and degree of weight-loss from self reported pre-illness (~6 months 
previously) stable weight documented.  Patients were classified as cachectic if they had 
weight-loss ≥5% according to the modern definition (1). Karnofsky performance score 
(KPS) was assessed in each patient by a single observer.  
 
Muscle biopsies 
All biopsies were taken at the start of open abdominal surgery under general anaesthesia. 
Patients had undergone an overnight fast. The edge of the Rectus abdominis was 
exposed and a 1cm
3
 specimen removed using sharp dissection.  Tissue samples were 
quickly cleaned of blood, flash frozen in liquid nitrogen and stored at -80°C until further 
analysis.  
 
Blood measures 
All blood samples were taken following an overnight fast. CRP level was measured 
using ELISA (Ely, UK).  A CRP ≥5mg/l (the upper limit of normal in our lab) was 
considered consistent with the presence of systemic inflammation. 
 
Protein Isolation 
Approximately 20mg of muscle was homogenised in 0.5ml of lysis buffer (Triton – 
X100 (1%), NaCl (150mM), Tris-HCl (50mM), EDTA (1mM), PMSF (1mM), protease 
inhibitors (Roche Diagnostics) (1 tablet per 10ml), water to 10ml) using a Powergen 
125 (Fisher Scientific) electric homogeniser.  Samples were left on ice for 15min prior 
to centrifuging at 13000rpm for 15min. The supernatant was removed, and protein 
concentration was determined by comparing equal volumes of sample solution to 
known standards using the Lowry method. Samples were then stored at -80°C.  
 
Nuclear protein extraction (for FOXO transcription factors) 
Approximately 20mg of muscle was resuspended in 180μl of low salt lysis buffer 
(10mM HEPES, 10mM KCl, 1.5mM MgCl2, 0.1mM EDTA, 0.1mM EGTA, 1mM 
DTT, 0.5mM PMSF, protease inhibitors (Roche Diagnostics) (1 tablet per 10ml)) and 
ground using a hand held homogeniser.  Samples were incubated on ice for 5min before 
two cycles of freeze-thaw lysis.  After a brief vortex, samples were centrifuged at 
4000rpm for 3min.  The supernatant was removed and the pellet (containing the nuclei) 
resuspended in 40μl high salt extraction buffer (20mM HEPES, 420mM NaCl, 1mM 
EDTA, 1mM EGTA, 25% Glycerol, 1mM DTT, protease inhibitors (Roche Diagnostics) 
(1 tablet per 10ml)).  Samples were incubated on ice for 30min with gentle mixing of 
the tubes every 5-10min.  Samples were centrifuged at 4000rpm for 5min at 4°C.  The 
supernatant which now contained the nuclear proteins was aliquoted into tubes and 
stored immediately at -80°C.  
 
Western Blotting 
20μg of protein from each sample was added to 3μl of 4 x LBS (0.5M Tris-HCl pH 6.8, 
20% glycerol, 4% SDS,  0.05% β-mercaptoethanol, 0.004% bromophenol blue) and 
boiled for 3 minutes.  Proteins were resolved using SDS-polyacrylamide gel 
electrophoresis at 160V for 45 mins. Proteins were transferred to a nitrocellulose 
membrane (80mA for 1 hour) using semi-dry transfer (Biorad).  Membranes were 
blocked with either 3% BSA/TBST (TBS, 0.05% Tween) overnight at 4°C or with 5% 
milk/TBST for 1hr at room temp. Incubation with primary antibody (1:1000) was 
carried out in either 3% BSA/TBST or 0.5% milk/TBST solution at room temperature 
for 2 hours or overnight at 4
o
C.  Membranes were washed with TBST and primary 
antibody binding detected using horseradish-peroxidase conjugated secondary 
antibodies (1:2000 to 1:5000).  Specific signal was detected using ECL (enhanced 
chemiluminescence) reagent (GE Healthcare) and exposure on photographic film 
(Kodak).  Films were scanned and densitometry values estimated using ImageJ (NIH) 
software.  All proteins were normalised to alpha-skeletal actin as a loading control, 
except for FOXO1/3a which, because they were nuclear protein extracts, were 
normalised to lamin A/C.  
 
Antibodies 
The primary antibodies used in the study were Akt, pAkt (Ser473), FOXO1, FOXO3a 
(Cell Signaling); lamin A/C (Santa Cruz Biotechnology Inc); dystrophin (MANDYS102 
(7D2)), β-dystroglycan (MANDAG2 (7D11)), (Developmental Studies Hybridoma 
Bank); β-sarcoglycan (abcam); myosin heavy chain (fast) (Sigma); alpha-skeletal actin 
(Novocaestra).  Secondary antibodies were anti-mouse or anti-rabbit: (Upstate). 
 
RNA Isolation 
Total RNA was extracted from approximately 20mg of muscle using TRIzol 
(Invitrogen) reagent according to the manufacturer’s directions.  The RNA pellet was 
resuspended in DEPC treated water and RNA concentration was determined using a 
Nanodrop spectrophotometer (LabTech International, UK).  RNA quality was assessed 
using 260/280, 230/260 ratios and the RIN score from the BioAnalyzer 2100 instrument 
(Agilent Technologies). 
 
Quantitative RT-PCR (qRT-PCR) 
Total RNA was extracted as described above. cDNA was prepared using 1μg RNA, 
TaqMan reverse transcription reagents (Applied Biosystems) and random hexamer 
primers (Applied Biosystems). Primers were designed to span introns using Primer 
Express 3.0 software (Applied Biosystems) and the primers were constructed by 
Invitrogen (Paisley, UK).  Primer sequences used were: BNIP3_Fw; GTC AAG TCG 
GCC GGA AAA TA, BNIP3_Rv; GCG CTT CGG GTG TTT AAA GA, 
GABARAPL1_Fw; CCA CCG CAA GGA GAC AGA AG, GABARAPL1_Rv; GAA AAT 
GTG ATG ACG GTG TGT GT, MAFBX_Fw; CCG GCT GTT GGA GCT GAT A, 
MAFBX_Rv; TTG GGC GAT GCC ACT CA, MURF1_Fw; GCT AGG CGT GGC TCT 
CAT TC, MURF1_Rv; TCC TGG ATC AGG CTC GAC TT. Samples were run on an 
ABI 7900HT Fast Real-Time PCR system (Applied Biosystems) in triplicates of 20 
microlitres per well using SYBR Green PCR Master Mix (Applied Biosystems) as per 
manufacturer’s instructions. Expression levels were normalised to ribosomal 18S RNA 
and results examined using the delta-delta CT method (21). 
 
Statistical analysis 
For analysis of qRT-PCR and Western blotting results, SPSSv19.0 was used.  
Mathematical transformation was performed when appropriate.  Student’s two tailed t 
test, Mann Whitney or Kruskal Wallis test were used to compare means between groups.  
Contingency tables were constructed where relevant and analysed by Chi squared test.  
Patients were divided into those who survived more than or less than one year post-
operatively (a meaningful surgical and oncological outcome).  ROC analysis was 
performed using this division and the cut-off which gave the highest sensitivity and 
specificity was manually selected.  Kaplan-Meier survival curves and log-rank 
comparison was used to assess differences in survival between groups.  Statistical 
significance was set at a p-value (two-tailed) of ≤0.05.   
 
Results 
107 patients were recruited in total (15 HC and 92 UGIC patients).  Demographics for 
the entire cohort are illustrated in Table 1.  Biopsies were used according to availability 
of tissue for different biomarkers.  There were four separate groups and the 
demographics for these are illustrated in Supplementary Table 1.  Supplementary 
Figure 1 shows the overlap between groups.  No significant differences were evident 
between these groups and the entire cohort.    
 
Compared with HC, cancer patients were older (mean (SD) age 65 (10) vs 56 (17) years, 
p=0.003), had higher average weight-loss (8.1 (9.3) vs 0 (0) %, p=0.001), lower BMI 
(25.7 (4.0) vs 28.0 (4.5) kg/m
2
, p=0.046) and a significantly lower KPS (89 (13) vs 100 
(0), p=0.001) (Table 1A).   
 
Within the cancer patient cohort, cachectic patients compared with non-cachectic 
patients had a larger proportion of females (19/51 vs 7/41, Chi squared p=0.033), were 
younger (63 (9) vs 68 (9) years, p=0.022), had shortened median survival (562 vs 846 
days, p=0.030), and a lower BMI (24.6 (3.7) vs 27.0 (4.0) kg/m
2
, p=0.004.  KPS was 
also significantly lower in cachectic compared with non-cachectic patients (86 (14) vs 
92 (10), p=0.020) (Table 1A).   
 
Variability of protein biomarkers in the presence of cancer and cachexia 
Results of the skeletal muscle biomarkers are illustrated in Figure 1. Level of total Akt 
protein was reduced in cancer patients compared with HC (0.49 (0.31) vs 0.89 (0.17), 
p=0.001), but there was no significant difference in pAkt protein level (0.47 (0.34) vs 
0.29 (0.2), p=0.104).  However, the ratio of pAkt to total Akt (indicative of Akt activity) 
was increased in cancer patients compared with HC (1.33 (1.04) vs 0.32 (0.21), 
p=0.002).   
 
Cachectic cancer patients had significantly higher levels of β-dystroglycan than non-
cachectic cancer patients (1.01 (0.16) vs 0.87 (0.20), p=0.007).  There was also a trend 
towards increased levels of β-sarcoglycan (0.63 (0.28) vs 0.55 (0.55), p=0.052). 
 
Variability of mRNA biomarkers in the presence of cancer and cachexia 
Results of the skeletal muscle biomarkers are illustrated in Figure 1. There was a trend 
towards an increase in expression of BNIP3 in cancer patients compared with HC (1.37 
(0.49) vs 1.07 (0.57), p=0.058 and a significantly increased expression of 
GABARAPL1 (1.60 (0.76) vs 1.10 (0.57), p=0.024).  No mRNA biomarkers related to 
the presence of cachexia. 
 
Variability of biomarkers associated with survival 
Patients who survived ≤1 year post-operatively compared with those who survived >1 
year had significantly higher average weight-loss (12.0 (11.1) vs 6.3 (8.0) %, p=0.007) 
and a lower KPS (83 (13) vs 91 (12), p=0.004) (Table 1B).   
 
Given that there are no ‘normal’ cut-offs for skeletal muscle protein levels or mRNA 
expression for potential markers, ROC analysis was performed.  There were no strong 
significant candidates, but there was a trend for MyHC, dystrophin and pAkt (area 
under the curves were 0.674 (p=0.069), 0.714 (p=0.070) and 0.669 (p=0.068) 
respectively).  Co-ordinates of the ROC curves were inspected and a cut-off of ≥0.87 
chosen for MyHC to give a sensitivity of 84.8% and specificity of 46.2%; a cut-off of 
≥0.31 chosen for dystrophin to give a sensitivity of 85.0% and specificity of 55.6%; and 
a cut-off of ≥0.19 chosen for pAkt to give a sensitivity of 87.5% and specificity of 
42.3%.  Kaplan-Meier survival analysis using these cut-offs (Figure 2) showed a 
significantly shorter survival for those with lower compared with higher MyHC levels 
(median survival 316 vs 1326 days, p=0.023) and lower compared with higher 
dystrophin levels (median survival 341 vs 660 days, p=0.008), but no significant 
difference between high and low pAkt levels (p=0.320).  Given the difference in 
survival for MyHC and dystrophin, the demographics of the low versus higher levels of 
MyHC and dystrophin groups were examined (Table 2).  None of the variables differed 
significantly between the groups for either MyHC or dystrophin.  
Discussion 
In this biomarker discovery study, we demonstrated suppression of total Akt protein 
levels in the skeletal muscle of cancer patients but with a relative increase in Akt 
activity.  There was also some evidence of increased autophagy in cancer patients. β-
dystroglycan appeared to relate to the presence of significant weight-loss in cancer 
patients.  Low MyHC and low dystrophin protein levels both related to shortened 
survival.   
 
In one of very few similar studies, Schmitt et al examined protein levels and 
phosphorylation status of muscle atrophy/hypertrophy pathway components in eight 
pancreatic cancer patients with cachexia compared with eight weight-stable cancer or 
pancreatitis patients (22).  They observed reduced levels of Akt, MyHC and FOXO1 in 
the cachectic group.  In the current study, which looked at a much larger cohort of 
patients with a variety of upper gastrointestinal cancers, along with non-cancer HC, we 
did not observe any differences in these markers between cachectic and non-cachectic 
patients.  We did, however, observe cancer patients (compared with non-cancer HC) to 
have a reduction in Akt levels, but with a relative increase in overall Akt activity 
(expressed as the ratio of pAkt to total Akt).  It should be noted that whilst FOXO3 
antibody and methodology for determining MyHC levels differed, the antibodies for 
FOXO1, Akt and pAkt were the same between the two studies and would thus not 
explain these contrasting results.  An alternative is that the observations of Schmitt et al 
may be tumour specific or reflect markers of more moderate cachexia whereas our 
observations relate to the presence of cancer alone or to cachexia earlier in the disease 
process.  Schmitt et al defined cachexia as >10% weight-loss in 6 months whereas for 
the current study, cachexia was defined as ≥5% weight-loss in line with recent 
definitions (1).  However, when we analysed our data according to a 10% weight-loss 
cut-off, the results for individual variables did not differ from using a 5% weight-loss 
cut-off (data not shown).  Therefore, another explanation would be that total protein 
turnover is suppressed in cancer patients (23) with a reduction in the available pool of 
Akt and that increased phosphorylation represents a compensatory mechanism.  In 
support of this, in COPD patients with cachexia, an increased ratio of pAkt to total Akt 
has also been observed with the suggestion that this represents an attempt to restore 
muscle mass (24;25). 
 
The muscle-specific E3 ubiquitin ligases, MuRF-1 and atrogin-1/MAFbx are commonly 
used to indicate activation of the UPP after the discovery that they were upregulated in 
several distinct models of atrophy (6).  Likewise, markers of autophagy have been 
shown to be increased in cachectic mice and under the control of FOXO3 (17).  
However, in the current study, FOXO transcription factors and the ubiquitin E3 ligases 
were similar between HC and cancer patients and were not influenced by the presence 
of cachexia.  Cancer patients did have increased expression of GABARAPL1 and a 
trend towards increased expression of BNIP3, both of which play a key role in 
autophagy.  However, we did not see either of these autophagy markers significantly 
relating to survival or weight-loss.  There was evidence of increased β-dystroglycan 
protein levels in cachectic patients and a trend towards increased protein levels of β-
sarcoglycan.  Dysregulation of the dystrophin glycoprotein complex (DGC) is a feature 
of muscular dystrophies and has been associated with cachexia (19).  In the context of 
muscular dystrophy there would normally be downregulation of all components of the 
DGC.  However, this has not been the case in cancer cachexia but neither has an 
increase in protein levels been demonstrated (19).  In a mouse model of muscular 
dystrophy treated with an AMPK activator, increased utrophin coincided with an 
increase in β-dystroglycan and resultant strengthening of the sarcolemma (26). It is 
therefore conceivable that the relationship between β-dystroglycan and cachexia seen in 
the current study represents an attempt at muscle membrane repair as it enters a more 
dysregulated state with progressive weight-loss.  Given that the current study is not 
mechanistic and utrophin was not investigated as a potential marker, this suggestion is 
speculative. 
 
It is striking that we demonstrated an association between low levels of structural 
muscle proteins and shortened survival.  The lack of significant demographic 
differences between the low and higher level MyHC/dystrophin groups suggests that 
they are bona fide markers of post-operative survival.  Perhaps lower levels of these 
structural proteins identify a susceptible population where muscle structure/membrane 
integrity has already started to become compromised.  Alterations in membrane 
structure and integrity have been demonstrated in C-26 tumour bearing mice which is 
thought to be due, at least in part, to disruption of the DGC (19).  This normally 
provides a strong mechanical link between the intracellular cytoskeleton and 
extracellular matrix (27).  Mutations in the DGC cause muscular dystrophies/ 
cardiomyopathy, and a link with human cancer cachexia has been made.  DGC 
deregulation was demonstrated in oesophago-gastric cancer patients and related to the 
presence of significant weight-loss (>10%) and systemic inflammation and to a 
shortened survival (19).   It is also thought that there is selective targeting of 
myofibrillar proteins, in particular MyHC, in cancer cachexia (7;10).  In addition, 
myofibrillar degradation appears to occur in a time dependent manner.  One animal 
study of muscle atrophy after denervation or fasting, demonstrated early targeting of 
thin filament components with subsequent loss of MyHC (20).  Adding to the concept 
that membrane damage is important in the pathogenesis of cancer cachexia, our lab has 
recently shown that the presence of various myosin species in the urine of patients with 
oesophago-gastric cancer relates to significant (>10%) weight-loss (11).  Our 
observations in the current study that patients with lower skeletal muscle dystrophin or 
MyHC protein levels are associated with a shortened survival are entirely consistent 
with this concept.  Therefore, measurements of these structural elements in skeletal 
muscle appear to be suitable biomarkers relating to survival in UGIC cancer patients. 
 
By comparing cachectic, non-cachectic and HC groups, this study evaluates the 
potential of certain variables to act as biomarkers of cachexia.  However, it is not 
possible to determine the precise role of these variables in cachexia by comparing the 
cachectic with non-cachectic groups.  The patients without cachexia at diagnosis 
represent a mixed group some of whom will remain weight-stable, but a significant 
other group will progress to cachexia and are therefore in a pre-cachectic state.  This 
heterogeneity within the weight-stable group potentially masked changes in some 
variables which may play a role in development of cachexia/pre-cachexia.  In order to 
further explore this area, longitudinal assessments of patients would be required to 
determine which individuals progress to losing weight after the initial biopsy.  However, 
the natural history of cachexia in this study population cannot be determined because 
the majority of patients subsequently underwent a potentially curative resection. 
 It is important to appreciate that this study is capturing a snapshot in time of what is 
really a journey comprising early, cachectic and refractory phases (1) in a heterogenous 
population at various points on this spectrum.  There is evidence that different 
proteolytic/synthetic pathways may be activated or repressed according to degree of 
weight-loss.  For example, in a study of lung cancer patients with mean weight-loss of 
2.9%, the lysosomal but not the UPP was activated (28), whereas in patients with gastric 
cancer and mean weight-losses of 5.2% and 5.6% have shown increases in components 
of the UPP (29;30).  There is also evidence in cancer patients (31) that UPP activity 
increases with weight-loss up to 12-19% and then declines as disease severity 
progresses. Likewise, a recent study of gastric cancer patients showed evidence of 
increase in calpains in patients with minimal or no weight-loss, but did not show any 
difference in expression of the ubiquitin E3 ligases in cancer compared with control 
patients (32).  Longitudinal studies in human cancer cachexia may be informative in this 
regard, but are difficult to carry out owing to the requirements for multiple assessments/ 
tissue samples in a frail population.  In addition, there may be varying responses among 
patients to adjuvant chemoradiotherapy, the influence of surgery, post-operative 
complications, concurrent illnesses (eg infections) and selective attrition which will add 
to the complexity of interpreting such studies.    
 
Non-cachectic patients were 5 years older than cachectic patients.  Sarcopenia of ageing 
has been well characterised and the non-cachectic group would thus have 5 extra years 
of age-related muscle wasting.  It is possible that this age gap may have influenced 
differences in levels of biomarkers between groups.  Conversely, a younger age at 
diagnosis of cancer is a risk factor for poorer outcome in certain tumour types (eg breast 
(33)).  Whether younger patients are more likely to suffer from cachexia or more 
aggressive weight-loss is not known, but represents an interesting area for future 
exploration. 
 
The potential biomarkers of cachexia in the current study were selected from evidence 
relating predominantly to muscle wasting in animal models.  The lack of association of 
biomarkers with cachexia may therefore simply reflect differences between animal and 
human cancer cachexia.  Whereas the majority of animal models of cachexia undergo 
rapid and profound weight-loss, human cancer cachexia is a chronic disease process.  
Furthermore, in humans, there will be added confounding factors such as level of 
baseline physical activity, bed rest, the presence of co-morbidities, dietary preferences, 
personal motivation and sickness behaviour.   
 
The majority of potential biomarkers that were evaluated related to protein degradation 
rather than synthetic pathways.  There is reasonable evidence to suggest that in muscle 
atrophy associated with ageing/ bed-rest, suppression of protein synthesis is of greater 
importance than increased degradation (34).  Furthermore, in patients with UGIC, our 
group recently found evidence of suppression of muscle protein turnover (23). It may be 
that future studies investigating biomarkers selected from anabolic pathways may 
identify candidates which relate more strongly to cachexia.   Alternatively, changes in 
muscle at the molecular level may not have a strong influence on muscle phenotype.  
Evidence of such dissociation has been demonstrated by Greenhaff et al in the skeletal 
muscle of healthy men.  They showed that increased amino acid and insulin availability 
led to changes in anabolic signalling molecules and components of the UPP which did 
not result in the expected corresponding alterations in muscle protein synthesis or 
breakdown (35).  Whether this also occurs in the context of human cancer cachexia 
remains to be elucidated. 
 
In conclusion, many of the key components of known muscle wasting pathways do not 
transpose directly to being robust biomarkers of cachexia.  Skeletal muscle Akt protein 
levels/phosphorylation status and GABARAPL1 expression are biomarkers relating to 
cancer and possibly early cachexia.  β-dystroglycan is a biomarker of weight-loss in 
cancer patients and MyHC and dystrophin are biomarkers associated with survival.  
This study highlights the complexity of biomarker research and provides impetus for 
further validation and discovery studies in order to identify robust diagnostic 
biomarkers and potential therapeutic targets in patients with cancer cachexia. 
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Table 1 – Patient demographics for (A) HC and cancer patients (with and without 
cachexia) and (B) cancer patients surviving ≤ 1 vs > 1 year.  Results are presented as 
mean ± SD or categorically except for median survival. Abbreviations: M, male; F, 
female; BMI, body mass index; CRP, C-reactive protein; KPS, Karnofsky performance 
score. 
 
A.   Control  All Cancer Cancer  Cancer   
       No cachexia Cachexia   
n=   15  92  41  51 
M/F   8/7  66/26  34/7  32/19† 
Age (yr)   56±17  65±10*  68±9  63±9† 
Weight-loss (%)  0.0±0.0  8.1±9.3* 0.8±3.0  13.9±8.6† 
Survival (days)  -  675  846  562† 
BMI (kg/m
2
)  28.0±4.5 25.7±4.0* 27.0±4.0 24.6±3.7† 
CRP (mg/l)  3.5±2.7  15.5±31.3 12.0±29.6 18.3±32.6 
CRP≥5mg/l (Y/N) 4/11  41/51  15/26  26/25 
KPS   100±0  89±13*  92±10  86±14† 
 
* = p<0.05 cancer vs control patients, † = p<0.05 cachectic vs non-cachectic patients 
 
B.   Survival ≤1yr Survival>1yr   
n=   27  64 
M/F   18/9  48/16 
Age (yr)   66±10  65±10 
Weight-loss (%)  12.0±11.1 6.3±8.0* 
Survival (days)  245  1195* 
BMI (kg/m
2
)  25.3±3.5 26.0±4.2 
CRP (mg/l)  18.0±36.3 14.6±29.4 
CRP≥5mg/l (Y/N) 16/11  25/39  
KPS   83±13  91±12* 
 
* = p<0.05 survival >1yr vs survival ≤1yr 
 
Table 2 – Patient demographics according to the ROC derived cut-offs for (A) MyHC 
and (B) Dystrophin. Results are presented as mean ± SD or categorically.  
Abbreviations: M, male; F, female; BMI, body mass index; CRP, C-reactive protein; 
KPS, Karnofsky performance score. 
 
  
A. MyHC  low (<0.87) high (≥0.87) 
n=   12  35 
M/F   7/5  21/14 
Age (yr)   63±7  64±10 
BMI (kg/m
2
)  24.9±4.4 25.4±3.8 
Weight-loss (%)  9.8±7.4  9.6±12.1  
Cachexia (Y/N)  9/3  20/15 
CRP (mg/l)  20.3±41.6 12.1±25.8 
CRP≥5mg/l (Y/N) 7/5  14/21 
KPS   88.2±10.8 92.1±12.1 
 
B. Dystrophin  low (<0.31) high (≥0.31) 
n=   8  21 
M/F   5/3  10/11 
Age (yr)   62±13  63±9 
BMI (kg/m
2
)  26.8±6.3 25.0±4.3 
Weight-loss (%)  9.5±7.5  9.7±11.3 
Cachexia (Y/N)  7/5  14/21 
CRP (mg/l)  45.8±52.3 11.8±22.4 
CRP≥5mg/l (Y/N) 5/3  8/13 
KPS   82.5±8.9 84.3±15.0 
 
 
Figure Legends 
 
Figure 1: Graphs showing (A) densitometry of protein biomarkers normalised to 
loading control or (B) delta-delta CT expression of mRNA biomarkers for HC and 
cancer patients (with and without cachexia). *p<0.05 HC vs all cancer, #p<0.05 no 
cachexia vs cachexia. 
 
Figure 2: Kaplan-Meier survival curves for patients with (A) low (<0.87) vs high 
(≥0.87) MyHC protein levels; Log Rank p=0.023 and (B) low (<0.31) vs high (≥0.31) 
dystrophin protein levels; Log Rank p=0.008. 
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Figure 2: 
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Supplementary Material 
 
Supplementary Table 1 
Individual cancer patient cohorts according to biomarkers evaluated. Abbreviations: M, 
male; F, female; BMI, body mass index; CRP, C-reactive protein; KPS, Karnofsky 
performance score. 
 
   1  2  3  4 
n=   42  52  47  29   
M/F   28/14  34/18  28/19  15/14 
Age (yr)   65±10  66±9  64±9  63±10 
BMI (kg/m
2
)  25.7±4.5 25.5±3.6 25.3±3.9 25.5±4.9 
Weight-loss (%)  7.5±9.5  8.9±8.0  9.7±11.0 9.6±10.3 
Cachexia (Y/N)  22/20  32/20  29/18  18/11 
CRP (mg/l)  20.7±38.7 17.4±32.1 14.2±30.3 21.2±35.8 
CRP≥5mg/l (Y/N) 20/22  26/26  21/26  23/16 
KPS   83.1±13.7 92.4±10.5 91.0±11.7 83.8±13.5 
 
1= Akt, pAkt, β-dystroglycan, β-sarcoglycan 
2= FOXO1, FOXO3a, BNIP3, GABARAPL1, MuRF1, MAFBx  
3= MyHC 
4= Dystrophin 
 
Supplementary Figure 1  
Visual representation of the overlap in patient groups for different biomarkers (shaded 
box indicates that biopsy material was used). 
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